Garden Biopharma

Zhejiang Garden Biopharmaceutical Co., Ltd., commonly known as Garden Biopharma, is a leading Chinese life sciences company specializing in the production of vitamins and pharmaceutical formulations. Founded in 2000 and headquartered in Dongyang, Zhejiang, the company is a global leader in the Vitamin D3 industrial chain, controlling a significant share of the market for lanolin cholesterol and vitamin D3 analogues. Garden Biopharma operates two primary segments: a nutrition segment focused on vitamins A, D3, E, and B6, and a pharmaceutical segment that develops high-barrier generic drugs for cardiovascular, respiratory, and neurological disorders. The company is listed on the Shenzhen Stock Exchange (300401) and continues to expand its portfolio through a "one vertical, one horizontal" strategy, integrating advanced chemical synthesis and biosynthesis technologies. Its commercial portfolio includes widely used medications such as valsartan/amlodipine, escitalopram, and levofloxacin, supported by large-scale GMP-certified manufacturing facilities.